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Background: The polymorphism Pro12Ala in peroxisome proliferator-activated receptorγ2 gene (PPARγ2) has been
reported to be associated with diabetic nephropathy (DN) in some studies, though the results remain inconclusive.
To explore this relationship between PPARγ2 Pro12Ala polymorphism and the susceptibility for DN, a cumulative
meta-analysis was performed in this study.
Method: PubMed, Medline, Embase and Web of Science databases have been systematically searched to identify
relevant studies. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated.
Results: 18 studies were included in this meta-analysis, involving 3,361 cases and 5,815 controls. The PPARγ2
Ala12 allele was significantly associated with decreased risk of DN based on dominant model (OR=0.778; 95%
CI=0.618–0.981; Pheterogeneity=0.008; P=0.034). In the stratified analysis by ethnicity, significantly decreased risks
were found among Caucasians for dominant model (OR=0.674; 95%CI=0.500–0.909; Pheterogeneity=0.079; P=0.010),
while there was no significant association was found in Asians.
Conclusions: The results from the present meta-analysis indicated that the Pro12Ala polymorphism in PPARγ2
gene is not a risk factor for DN in type 2 diabetes (T2D). Further large and well-designed studies are needed to
confirm this conclusion.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/7491348341027320.
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Diabetic nephropathy is the leading cause of end-stage
renal disease (ESRD) worldwide, and it is estimated that
20% of T2D patients reach ESRD during their lifetime
[1]. The pathogenesis of DN has many genetic and en-
vironmental factors contributing to its development
and progression. The risk of developing DN has been
linked to different chromosomes, including chromo-
some 3, to which the peroxisome proliferators-activated* Correspondence: leiwang_sy@163.com
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reproduction in any medium, provided the orreceptor (PPAR) gene has been mapped, particularly to
the PPAR gamma (PPARG) nuclear receptor, which is
mainly expressed in adipose tissue but is also found in
pancreatic beta cells, vascular endothelium, and macro-
phage [2,3].
PPAR-γ2 is a nuclear receptor that serves important
roles in intermediate metabolism. The PPARG gene is
located on chromosome 3p [2]. The Pro12Ala poly-
morphism of the PPARG gene, a Pro-to-Ala exchange
that results in the substitution of proline with alanine at
codon 12, was associated with reductions in both DNA
binding and transcriptional activity in vitro, and Ala12
carriers showed significant improvement in insulin sen-
sitivity [4,5]. The Pro12Ala polymorphism in the PPARGtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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kwon, many epidemiologic studies investigated the po-
tential association of PPARG gene polymorphisms with
susceptibility to DN. However, these studies have
reported inconclusive results.
One putative genetic determinant of DN is the
Pro12Ala polymorphism in the gene encoding PPARg.
PPARg, a member of the nuclear hormone receptor
superfamily of ligand-activated transcription factors,
plays a key role in regulating the expression of numer-
ous genes involved in lipid metabolism, metabolic syn-
drome, inflammation, and atherosclerosis [6,7]. The
P12A single-nucleotide polymorphism (SNP) located in
the adipocyte-specific PPARg2 isoform has been associ-
ated with lower nephropathy in T2D [8,9]. The under-
lying molecular mechanism of this polymorphism
appears to be, in vitro, a moderate reduction in DNA-
binding activity and reduced transcriptional activity
[4,10]. In the present study, we examined the relation-




A comprehensive literature search was performed using
the PubMed, Medline, Embase, and Web of Science
database for relevant articles published (last search
updated in May. 2013) with the following key words
“PPARγ2”, “polymorphism” and “diabetic nephropathy”.
Additional studies were identified by hand searching ref-
erences in original articles and review articles. Authors
were contacted directly regarding crucial data not
reported in original articles. The search was limited to
human studies. All eligible studies were retrieved, and
their bibliographies were checked for other relevant pub-
lications. When the same sample was used in several
publications, only the most complete study was included
following careful examination.
Inclusion criteria
The included studies have to meet the following criteria:
(1) only the case–control studies were considered; (2)
evaluated the PPARγ2 Pro12Ala polymorphism and DN
risk; (3) the genotype distribution of the polymorphism
in cases and controls were described in details, and the
results were expressed as odds ratio (OR) and corre-
sponding 95% confidence interval (95% CI).
Exclusion criteria
Major reasons for exclusion of studies were as follows: (1)
not for DN research; (2) only case population; (3) dupli-
cate of previous publication; and (4) the distribution of ge-
notypes among controls are not in Hardy–Weinberg
equilibrium (P <0.01).Data extraction
Information was carefully extracted from all eligible
studies independently by two investigators according to
the inclusion criteria listed above. The following data
were collected from each study: first author’s name, year
of publication, country of origin, ethnicity, source of
controls, genotyping method, match, sample size, and
numbers of cases and controls in the PPARγ2 Pro12Ala
genotypes whenever possible. Ethnicity was categorized
as “Caucasian” and “Asian”. When a study did not state
which ethnic groups were included or if it was impos-
sible to separate participants according to phenotype,
the sample was termed as “mixed population”. We did
not define any minimum number of patients to include
in this meta-analysis. Articles that reported different eth-
nic groups and different countries or locations, we con-
sidered them different study samples for each category
cited above.
Statistical analysis
Crude odds ratios (ORs) together with their correspond-
ing 95% CIs were used to assess the strength of associ-
ation between the PPARγ2 Pro12Ala polymorphism and
DN risk. The pooled ORs were performed for dominant
comparison model (Ala-carrier vs Pro/Pro). Between-
study heterogeneity was assessed by calculating Q-
statistic (Heterogeneity was considered statistically
significant if P < 0.10) [11] and quantified using the I2
value, Venice criteria [12] for the I2 test included:
“I2<25% represents no heterogeneity, I2=25–50% repre-
sents moderate heterogeneity, I2= 50–75% represents
large heterogeneity, and I2 >75% represents extreme het-
erogeneity”. If results were not heterogeneous, the
pooled ORs were calculated by the fixed-effect model
(we used the Q-statistic, which represents the magni-
tude of heterogeneity between-studies) [13]. Otherwise,
a random-effect model was used (when the heterogen-
eity between-studies were significant) [14]. We also
performed subgroup analysis by ethnicity (Caucasian
and Asian). Moreover, sensitivity analysis was performed
by excluding a single study each time. In addition, we also
ranked studies according to sample size, and then repeated
this meta-analysis. Begg’s funnel plots [15] and Egger’s lin-
ear regression test [16] were used to assess publication
bias. All of the calculations were performed using STATA
version 12.0 (STATA Corporation, College Station, TX).
Results
Study characteristics
Studies relevant to the searching words were retrieved
originally. 18 publications addressing the association be-
tween PPARγ2 Pro12Ala polymorphism and DN risk
were preliminarily eligible [8,9,17-30]. Table 1 presents
the main characteristics of these studies. There were a
Table 1 Main characteristics of these studies included in this meta-analysis
First author Year Country Ethnicity Genotype
method
Cases Controls HWE
Pro/ Pro Ala-carrier Pro/ Pro Ala-carrier
Mori et al. 2001 Japanese Asian PCR-RFLP 580 28 982 42 Yes
Herrmann et al. 2002 German Caucasian PCR-RFLP 154 43 144 59 Yes
Caramori et al. 2003 Brazilian Caucasian PCR-RFLP 93 11 169 43 Yes
Wu et al. 2004 Chinese Asian PCR-RFLP 194 26 102 6 Yes
Maeda et al. 2004 Japanese Asian PCR-RFLP 46 15 55 24 Yes
Pollex et al. 2007 Canadian Caucasian PCR-RFLP 94 3 55 7 Yes
Erdogan et al. 2007 Turk Asian PCR-RFLP 43 0 47 1 Yes
Wei et al. 2008 Chinese Asian PCR-RFLP 68 14 89 10 Yes
Li et al. 2008 Chinese Asian PCR 150 15 77 17 Yes
Wu et al. 2009 Taiwanese Asian Taqman 157 18 197 17 Yes
De Cosmo et al. 2009 Italian Caucasian Taqman 86 7 856 170 Yes
Liu et al. 2010 Chinese Asian PCR-RFLP 499 33 199 29 Yes
Lapice et al. 2010 Italian Caucasian PCR-RFLP 53 2 606 89 Yes
Zhu et al. 2011 Chinese Asian PCR-RFLP 39 2 33 4 Yes
De Cosmo et al1 2011 Italian Caucasian SBE 221 40 499 81 Yes
De Cosmo et al2 2011 Italian Caucasian Taqman 224 30 316 53 Yes
De Cosmo et al3 2011 Italian Caucasian ASA 207 25 422 60 Yes
Zhang et al. 2012 Indian Asian PCR-RFLP 113 28 206 49 Yes
PCR-RFLP: Polymerase Chain Reaction-Restriction Fragment Length Polymorphism; PCR: Polymerase Chain Reaction; SBE: Single-Base Extension; ASA: Allele-
Specific Amplification; 1,2,3: Different studies in one publication; HWE: Hardy–Weinberg Equilibrium; Yes: PHWE value>0.05.Reaction; SBE: Single-Base Extension;
ASA: Allele-Specific Amplification; 1,2,3: Different studies in one publication; HWE: Hardy–Weinberg Equilibrium; Yes: PHWE value>0.05.
Figure 1 Forest plots of the meta-analysis for the association between PPARγ2 Pro12Ala and nephropathy in type 2 diabetes patients.
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10 groups of Asians. Given the low frequency of Ala al-
lele, even in some studies, Ala homozygous individuals
are absent, and only the dominant model was investi-
gated, comparing Ala carriers to Pro/Pro. We also
assessed the deviation of Hardy-Weinberg equilibrium
in control subjects, and the results demonstrated that all
the distribution of genotypes in the controls of all stud-
ies was in agreement with Hardy–Weinberg equilibrium.
Meta-analysis results
Overall, the Pro12Ala polymorphism was found to be
significantly associated with decreased risk of T2D DN
(OR=0.778; 95%CI=0.618–0.981; Pheterogeneity=0.008;
P=0.034) (Figure 1). Both the Cochran Q test and esti-
mate of I2 revealed significant heterogeneity among the
constituent studies (Pheterogeneity=0.008; I
2=50.1%). To
avoid the influence of heterogeneity among the included
studies, subgroup analyses were distinctively carried out
according to the ethnicity. In the stratified analysis by
ethnicity, significantly decreased risks were found among
Caucasians for dominant model (Ala carrier vs Pro/Pro:
OR=0.674; 95%CI=0.500–0.909; Pheterogeneity=0.079;Figure 2 Subgroup meta-analysis was held by ethnicity for the associ
diabetes patients.P=0.010), while there was no significant association was
found under the same genetic model (OR=0.917; 95%
CI=0.639-1.315; Pheterogeneity=0.019; P=0.637) (Figure 2).
Significant heterogeneity was found in Asian populations
(Pheterogeneity=0.019; I
2= 54.7%), but not found in Cauca-
sian populations (Pheterogeneity=0.079; I
2=44.9%).
Sensitivity analysis
To test the stability of the pooled results, one-way sensi-
tivity analyses were performed. A single study involved
in the meta-analysis was deleted each time to reflect the
influence of the individual data set to the pooled ORs,
no other single study influenced the pooled OR qualita-
tively, suggesting that the results of this meta-analysis
were stable (Figure 3).
Publication bias
Begg’s funnel plot and Egger’s test were performed to
assess the publication bias of the literature. The shapes
of the funnel plots did not reveal any evidence of obvi-
ous asymmetry (PBegg=0.472) (Figure 4). Furthermore,
Egger’s test was used to provide statistical evidence
for funnel plot symmetry. The results still did notation between PPARγ2 Pro12Ala and nephropathy in type 2
Figure 3 One-way sensitivity analysis of the pooled ORs and 95% CI for the overall analysis, omitting each dataset in
the meta-analysis.
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(Figure 5).
Discussion
It is well recognized that there is individual susceptibility
to the DN even with the same environmental exposure.
Host factors, including polymorphisms of genes involved
in this formation of DN may have accounted for thisFigure 4 Begg funnel plot analysis to detect potential publication biadifference. Therefore, genetic susceptibility to DN has
been a research focus in scientific community. Recently,
genetic polymorphisms of the PPARγ2 Pro12Ala gene in
the etiology of DN have drawn increasing attention. Pre-
vious results of the studies on the relationship between
PPARγ2 Pro12Ala polymorphisms and DN risk were
contradictory. These inconsistent results are possibly be-
cause of a small effect of the polymorphism on DN risks.
Figure 5 Egger’s test was held to detect potential publication bias.
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studies. A meta-analysis is a powerful strategy because it
potentially investigates a large number of individuals and
can estimate the effect of a genetic factor on the risk of
the disease [31-35]. To better understanding of this asso-
ciation, a pooled analysis with a large sample, subgroup
analysis performed, and heterogeneity explored is neces-
sary to provide a quantitative approach for combining
the results of various studies with the same topic, and
for estimating the real association in this meta-analysis.
The present study including 3,361 cases and 5,815
controls from 18 published case–control studies, ex-
plored the association between a potentially functional
polymorphism, PPARγ2 Pro12Ala and T2D DN risk. We
found that there was evidence that the variant genotypes
of the PPARγ2 were associated with a significant de-
creased overall risk of DN. When stratified by ethnicity,
Caucasians with the Ala carrier showed a decreased risk
of DN compared with those with the Pro/Pro genotype.
However, Asians did not show the same results.
Some limitations of this meta-analysis should be men-
tioned. Firstly, bladder cancer is a multifactorial disease
that results from complex interactions between many
environmental and genetic factors. This means that
there will not be single gene or single environmental fac-
tor that has large effects on DN susceptibility. Our re-
sults were based on unadjusted estimates, while a more
precise analysis should be conducted if individual data
were available, which would allow for the adjustment by
other covariates including age, sex, family history, envir-
onmental factors and lifestyle. Secondly, the number ofsubjects was relatively small, not having enough statis-
tical power to explore the real association. Thirdly, the
controls were not uniformly defined. Finally, there were
only two ethnic decent populations. So, further large
and well-designed studies are needed to confirm this
conclusion.
Conclusion
This meta-analysis suggests that the PPARγ2 Pro12Ala
polymorphism is not a risk factor for developing T2D
DN. Moreover, gene–gene and gene–environment inter-
actions should also be considered in future analysis.
Such studies taking these factors into account may even-
tually lead to our better, comprehensive understanding
of the association between the PPARγ2 Pro12Ala poly-
morphism and T2D DN risk.
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